Cargando…
Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adve...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313334/ https://www.ncbi.nlm.nih.gov/pubmed/35885042 http://dx.doi.org/10.3390/biomedicines10071737 |
_version_ | 1784754054821314560 |
---|---|
author | Kuzmanovszki, Daniella Kiss, Norbert Tóth, Béla Kerner, Tünde Tóth, Veronika Szakonyi, József Lőrincz, Kende Hársing, Judit Imrédi, Eleonóra Pfund, Alexa Szabó, Ákos Brodszky, Valentin Rencz, Fanni Holló, Péter |
author_facet | Kuzmanovszki, Daniella Kiss, Norbert Tóth, Béla Kerner, Tünde Tóth, Veronika Szakonyi, József Lőrincz, Kende Hársing, Judit Imrédi, Eleonóra Pfund, Alexa Szabó, Ákos Brodszky, Valentin Rencz, Fanni Holló, Péter |
author_sort | Kuzmanovszki, Daniella |
collection | PubMed |
description | Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adverse events (irAEs). The majority of the available data are based on clinical trials, where the investigated subjects often do not adequately represent the general patient population of the everyday practice. Although there is a niche of objective biomarkers for the future treatment response of ICIs, certain studies suggest that irAEs may be predictive. The aim of this study was to carry out a retrospective analysis of treatment data from patients with advanced melanoma, treated with a single anti-PD-1 agent (pembrolizumab or nivolumab) during a 77-month-long period. Treatment efficacy and occurrence of adverse events were analyzed to identify potential predictive markers. Primary and secondary endpoints were the overall survival (OS) and progression-free survival (PFS). In our cohort, we demonstrated that the occurrence of more than one irAE showed a correlation with response to PD-1 ICI therapy and improved the OS and PFS. Our study suggests, that the grade of toxicity of the irAE may affect the survival rate. |
format | Online Article Text |
id | pubmed-9313334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93133342022-07-26 Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study Kuzmanovszki, Daniella Kiss, Norbert Tóth, Béla Kerner, Tünde Tóth, Veronika Szakonyi, József Lőrincz, Kende Hársing, Judit Imrédi, Eleonóra Pfund, Alexa Szabó, Ákos Brodszky, Valentin Rencz, Fanni Holló, Péter Biomedicines Article Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adverse events (irAEs). The majority of the available data are based on clinical trials, where the investigated subjects often do not adequately represent the general patient population of the everyday practice. Although there is a niche of objective biomarkers for the future treatment response of ICIs, certain studies suggest that irAEs may be predictive. The aim of this study was to carry out a retrospective analysis of treatment data from patients with advanced melanoma, treated with a single anti-PD-1 agent (pembrolizumab or nivolumab) during a 77-month-long period. Treatment efficacy and occurrence of adverse events were analyzed to identify potential predictive markers. Primary and secondary endpoints were the overall survival (OS) and progression-free survival (PFS). In our cohort, we demonstrated that the occurrence of more than one irAE showed a correlation with response to PD-1 ICI therapy and improved the OS and PFS. Our study suggests, that the grade of toxicity of the irAE may affect the survival rate. MDPI 2022-07-19 /pmc/articles/PMC9313334/ /pubmed/35885042 http://dx.doi.org/10.3390/biomedicines10071737 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kuzmanovszki, Daniella Kiss, Norbert Tóth, Béla Kerner, Tünde Tóth, Veronika Szakonyi, József Lőrincz, Kende Hársing, Judit Imrédi, Eleonóra Pfund, Alexa Szabó, Ákos Brodszky, Valentin Rencz, Fanni Holló, Péter Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study |
title | Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study |
title_full | Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study |
title_fullStr | Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study |
title_full_unstemmed | Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study |
title_short | Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study |
title_sort | anti-pd-1 monotherapy in advanced melanoma—real-world data from a 77-month-long retrospective observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313334/ https://www.ncbi.nlm.nih.gov/pubmed/35885042 http://dx.doi.org/10.3390/biomedicines10071737 |
work_keys_str_mv | AT kuzmanovszkidaniella antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT kissnorbert antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT tothbela antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT kernertunde antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT tothveronika antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT szakonyijozsef antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT lorinczkende antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT harsingjudit antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT imredieleonora antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT pfundalexa antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT szaboakos antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT brodszkyvalentin antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT renczfanni antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy AT hollopeter antipd1monotherapyinadvancedmelanomarealworlddatafroma77monthlongretrospectiveobservationalstudy |